Patient centered guidelines for the laboratory diagnosis of Gaucher disease type 1

• Autores: Dardis, A.; Michelakakis, H.; Rozenfeld, Paula Adriana; Fumic, K.; Wagner, J.; Pavan, E.; Fuller, M.; Revel Vilk, S.; Hughes, D.; Cox, T.; Aerts, J.
• Año de publicación: 2022
• Idioma: inglés
• Tipo de recurso: artículo
• Materia: BIOMARKERS; ENZYME ACTIVITY; GAUCHER DISEASE; GENETIC TESTING
• Institución: Consejo Nacional de Investigaciones Científicas y Técnicas

Gaucher disease (GD) is an autosomal recessive lysosomal storage disorder due to the deficient activity of the acid beta-glucosidase (GCase) enzyme, resulting in the progressive lysosomal accumulation of glucosylceramide (GlcCer) and its deacylated derivate, glucosylsphingosine (GlcSph). GCase is encoded by the GBA1 gene, located on chromosome 1q21 16 kb upstream from a highly homologous pseudogene. To date, more than 400 GBA1 pathogenic variants have been reported, many of them derived from recombination events between the gene and the pseudogene. In the last years, the increased access to new technologies has led to an exponential growth in the number of diagnostic laboratories offering GD testing. However, both biochemical and genetic diagnosis of GD are challenging and to date no specific evidence-based guidelines for the laboratory diagnosis of GD have been published. The objective of the guidelines presented here is to provide evidence-based recommendations for the technical implementation and interpretation of biochemical and genetic testing for the diagnosis of GD to ensure a timely and accurate diagnosis for patients with GD worldwide. The guidelines have been developed by members of the Diagnostic Working group of the International Working Group of Gaucher Disease (IWGGD), a non-profit network established to promote clinical and basic research into GD for the ultimate purpose of improving the lives of patients with this disease. One of the goals of the IWGGD is to support equitable access to diagnosis of GD and to standardize procedures to ensure an accurate diagnosis. Therefore, a guideline development group consisting of biochemists and geneticists working in the field of GD diagnosis was established and a list of topics to be discussed was selected. In these guidelines, twenty recommendations are provided based on information gathered through a systematic review of the literature and two different diagnostic algorithms are presented, considering the geographical differences in the access to diagnostic services. Besides, several gaps in the current diagnostic workflow were identified and actions to fulfill them were taken within the IWGGD. We believe that the implementation of recommendations provided in these guidelines will promote an equitable, timely and accurate diagnosis for patients with GD worldwide.
Fil: Dardis, A.. Academic Hospital Of Udine; Italia
Fil: Michelakakis, H.. Institute Of Child Health; Grecia
Fil: Rozenfeld, Paula Adriana. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - La Plata. Instituto de Estudios Inmunológicos y Fisiopatológicos. Universidad Nacional de La Plata. Facultad de Ciencias Exactas. Instituto de Estudios Inmunológicos y Fisiopatológicos; Argentina
Fil: Fumic, K.. University Hospital Centre Zagreb; Croacia
Fil: Wagner, J.. No especifíca;
Fil: Pavan, E.. Academic Hospital Of Udine; Italia
Fil: Fuller, M.. University of Adelaide; Australia
Fil: Revel Vilk, S.. Shaare Zedek Medical Center; Israel. The Hebrew University of Jerusalem; Israel
Fil: Hughes, D.. University College London; Estados Unidos
Fil: Cox, T.. University of Cambridge; Reino Unido
Fil: Aerts, J.. Leiden Institute of Chemistry; Países Bajos